Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.57 |
| ▸ | WNT3A | P56704 | 3/20 | 0.57 |
| ▸ | MAOB | P27338 | 8/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.51 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.51 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29643714 | 1.00 | NPC1 (0.58) | NPC1RAB9ACTNNB1WNT3AMAOB | |
| SCHEMBL23063836 | 0.88 | GSK3B (0.56) | NPC1RAB9ACTNNB1WNT3AMAOB | |
| SCHEMBL29643878 | 0.87 | MAOB (0.55) | NPC1RAB9AMAOBMAP4K4CLK2 | |
| SCHEMBL347171 | 0.87 | MAOB (0.55) | NPC1RAB9AMAOBMAP4K4CLK2 | |
| SCHEMBL28887308 | 0.86 | MAOB (0.50) | NPC1RAB9ACTNNB1WNT3AMAOB | |
| SCHEMBL30074092 | 0.83 | CTNNB1 (0.53) | NPC1RAB9ACTNNB1WNT3AMAOB | |
| SCHEMBL27836079 | 0.83 | MAOB (0.58) | NPC1RAB9ACTNNB1WNT3AMAOB | |
| SCHEMBL145658 | 0.83 | CTNNB1 (0.60) | NPC1RAB9ACTNNB1WNT3AMEN1 | |
| SCHEMBL29925697 | 0.83 | CTNNB1 (0.60) | NPC1RAB9ACTNNB1WNT3AMEN1 | |
| SCHEMBL27836080 | 0.83 | CTNNB1 (0.53) | NPC1RAB9ACTNNB1WNT3AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112573978-B | High-efficiency halogenation synthesis method of aryl halide | 北京大学 | 2022-05-13 | — | — | CN | claimed |
| CN-112573978-A | High-efficiency halogenation synthesis method of aryl halide | 北京大学 | 2021-03-30 | — | — | CN | claimed |
| EP-1628972-B1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-04-22 | — | — | EP | claimed |
| US-12612412-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-20 | — | — | US | disclosed |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-11-13 | — | — | US | disclosed |
| EP-4610260-A1 | ARYL HETEROCYCLIC KV1.3 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Shenshi Wise Technology Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| WO-2004101556-A1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1479675-A1 | Indazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
| EP-1438308-A1 | N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1380576-A1 | NOVEL 1H-INDAZOLE COMPOUND | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-09-18 | — | — | US | disclosed |
| WO-2003037896-A1 | N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | NPC1 2033/4885RAB9A 3313/4885CTNNB1 4466/4885 |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | SF1, SF3A1, SFXN1 | NPC1 2279/4885RAB9A 4417/4885CTNNB1 1727/4885 |
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | CYP1B1, ABCB1, NAT1 | NPC1 220/4885RAB9A 1422/4885CTNNB1 819/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | NPC1 1171/4885RAB9A 2697/4885CTNNB1 425/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | NPC1 837/4885RAB9A 85/4885CTNNB1 2647/4885 |
| US-12612412-B2 | Antiviral heterocyclic compounds | ZC3HAV1, NHERF1, HM13 | NPC1 792/4885RAB9A 352/4885CTNNB1 442/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | NPC1 1729/4885RAB9A 4351/4885CTNNB1 789/4885 |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | WRN, RECQL, BLM | NPC1 2175/4885RAB9A 2157/4885CTNNB1 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.